Treatment of diabetic kidney disease of stage Ⅲ-Ⅳ with Yiqi Wenyang Huoxue therapy: A meta-analysis

• 作者: Li-Sha Yuan Ning Zhang Rong-Lu Yang Fang-Ning Yu Xing-Yun Guo
• 来源期刊: 海南医科大学学报（英文版）
• 年，卷（期）: 2022,（2）
• 所属期刊栏目: Original article
• 页码范围: 53-59
• 页数: 7页
• 语种: 英文

摘要

Objective: To systematically evaluate the effect of Yiqi Wenyang Huoxue therapy in treating diabetic kidney disease(DKD) of stage Ⅲ-Ⅳ. Method: The relevant literature was retrieved by computer from CNKI, Wanfang and VIP databases,CBM,PubMed,EMBase,Cochrane Library and Web of Science. Articles screening and data extraction were performed by two researchers separately and independently. The Meta-analysis was conducted with RevMan 5.3. Results: A total of 10 randomized controlled trials were collected,including 778 cases with DKD. Meta-analysis showed that the Yiqi Wenyang Huoxue Method combined with western medicine basic treatment could reduce 24hUTP[MD=-0.36, 95％CI (-0.46, -0.26), P <0.00001], UAER[MD=-36.72,95％CI (-47.21, -26.23), P<0.00001], Scr[MD= -16.28, 95％CI(-20.59,-11.97),P<0.00001],BUN[MD=-1.45,95％CI(-1.76,-1.14), P <0.00001], TC[MD=-0.64, 95％CI(-1.07,-0.21), P=0.004].There was also a reduction in HbA1c[MD=-0.50,95％CI (-0.94, -0.05),P =0.03], but the difference is not significant. Conclusion: Based on the current evidence, for the treatment of DKD of stage Ⅲ-IV, basic western medicine treatment combined with Yiqi Wenyang Huoxue method may better reduce urine protein, total cholesterol levels and improve renal function. The conclusion of this study needs to be further researched by high-quality studies, because that the quality of the included studies is generally low.